Table of Contents
ISRN Pharmacology
Volume 2013, Article ID 546314, 7 pages
http://dx.doi.org/10.1155/2013/546314
Research Article

N-Phenylpropyl-N′-(3-methoxyphenethyl)piperazine (YZ-185) Attenuates the Conditioned-Rewarding Properties of Cocaine in Mice

1Department of Psychological Sciences, 203 McAlester Hall, University of Missouri, Columbia, MO 65211, USA
2Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
3MU Research Reactor Center, University of Missouri, Columbia, MO 65212, USA
4Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 65201, USA
5Departments of Radiology, and Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
6Center for Translational Neuroscience, College of Medicine, University of Missouri, Columbia, MO 65211, USA

Received 12 July 2013; Accepted 7 August 2013

Academic Editors: R. Fantozzi and R. Villalobos-Molina

Copyright © 2013 Andrew S. Sage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Bardo and R. A. Bevins, “Conditioned place preference: what does it add to our preclinical understanding of drug reward?” Psychopharmacology, vol. 153, no. 1, pp. 31–43, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. Huston, M. A. Silva, B. Topic, and C. P. Muller, “What's conditioned in conditioned place preference?” Trends in Pharmacological Sciences, vol. 34, pp. 162–166, 2013. View at Google Scholar
  3. M. T. Bardo, “Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens,” Critical Reviews in Neurobiology, vol. 12, no. 1-2, pp. 37–67, 1998. View at Google Scholar · View at Scopus
  4. F. S. Hall, I. Sora, J. Drgonova, X. Li, M. Goeb, and G. R. Uhl, “Molecular mechanisms underlying the rewarding effects of cocaine,” Annals of the New York Academy of Sciences, vol. 1025, pp. 47–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Hyman, R. C. Malenka, and E. J. Nestler, “Neural mechanisms of addiction: the role of reward-related learning and memory,” Annual Review of Neuroscience, vol. 29, pp. 565–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Katz, T. Su, T. Hiranita et al., “A role for sigma receptors in stimulant self administration and addiction,” Pharmaceuticals, vol. 4, no. 6, pp. 880–914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. R. Matsumoto, Y. Liu, M. Lerner, E. W. Howard, and D. J. Brackett, “σ receptors: potential medications development target for anti-cocaine agents,” European Journal of Pharmacology, vol. 469, no. 1–3, pp. 1–12, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Maurice and P. Romieu, “Involvement of the sigma1 receptor in the appetitive effects of cocaine,” Pharmacopsychiatry, vol. 37, supplement 3, pp. S198–S207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Fritz, S. Klement, R. El Rawas, A. Saria, and G. Zernig, “Sigma1 receptor antagonist BD1047 enhances reversal of conditioned place preference from cocaine to social interaction,” Pharmacology, vol. 87, no. 1-2, pp. 45–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Romieu, R. Martin-Fardon, and T. Maurice, “Involvement of the σ1 receptor in the cocaine-induced conditioned place preference,” NeuroReport, vol. 11, no. 13, pp. 2885–2888, 2000. View at Google Scholar · View at Scopus
  11. P. Romieu, J. Meunier, D. Garcia et al., “The sigma1 (σ1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming,” Psychopharmacology, vol. 175, no. 2, pp. 154–162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Xu, M. J. Robson, W. Szeszel-Fedorowicz et al., “CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain,” Pharmacology Biochemistry and Behavior, vol. 101, no. 1, pp. 174–180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Mori, M. Rahmadi, K. Yoshizawa, T. Itoh, M. Shibasaki, and T. Suzuki, “Inhibitory effects of SA4503 on the rewarding effects of abused drugs,” Addiction Biology, 2012. View at Publisher · View at Google Scholar
  14. K. R. Rodvelt, C. E. Oelrichs, L. R. Blount et al., “The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine,” Drug and Alcohol Dependence, vol. 116, no. 1–3, pp. 203–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. R. Matsumoto, F. H. Potelleret, A. MacK, B. Pouw, Y. Zhang, and W. D. Bowen, “Structure-activity comparison of YZ-069, a novel σ ligand, and four analogs in receptor binding and behavioral studies,” Pharmacology Biochemistry and Behavior, vol. 77, no. 4, pp. 775–781, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. Sage, C. E. Oelrichs, D. C. Davis et al., “Effects of N-phenylpropyl-N′-substituted piperazine sigma receptor ligands on cocaine-induced hyperactivity in mice,” Pharmacology, Biochemistry and Behavior, vol. 110, pp. 201–207, 2013. View at Google Scholar
  17. A. A. Braun, M. R. Skelton, C. V. Vorhees, and M. T. Williams, “Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents,” Pharmacology Biochemistry and Behavior, vol. 97, no. 3, pp. 406–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. K. Kulkarni, K. Singh, and M. Bishnoi, “Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 29, no. 5, pp. 343–348, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. K. Shepherd, S. S. Grewal, A. Fletcher, D. J. Bill, and C. T. Dourish, “Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety,” Psychopharmacology, vol. 116, no. 1, pp. 56–64, 1994. View at Google Scholar · View at Scopus
  20. L. L. Coughenour, J. R. McLean, and R. B. Parker, “A new device for the rapid measurement of impaired motor function in mice,” Pharmacology Biochemistry and Behavior, vol. 6, no. 3, pp. 351–353, 1977. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Shiotsuki, K. Yoshimi, Y. Shimo et al., “A rotarod test for evaluation of motor skill learning,” Journal of Neuroscience Methods, vol. 189, no. 2, pp. 180–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Calcagnetti and M. D. Schechter, “Extinction of cocaine-induced place approach in rats: a validation of the “biased” conditioning procedure,” Brain Research Bulletin, vol. 30, no. 5-6, pp. 695–700, 1993. View at Google Scholar · View at Scopus
  23. R. Martin-Fardon, T. Maurice, H. Aujla, W. D. Bowen, and F. Weiss, “Differential effects of σ1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward,” Neuropsychopharmacology, vol. 32, no. 9, pp. 1967–1973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Romieu, M. Lucas, and T. Maurice, “σ1 receptor ligands and related neuroactive steroids interfere with the cocaine-induced state of memory,” Neuropsychopharmacology, vol. 31, no. 7, pp. 1431–1443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. K. W. Jones, L. M. Bauerle, and V. J. DeNoble, “Differential effects of σ and phencyclidine receptor ligands on learning,” European Journal of Pharmacology, vol. 179, no. 1-2, pp. 97–102, 1990. View at Google Scholar · View at Scopus
  26. E. J. Cobos, J. M. Entrena, F. R. Nieto, C. M. Cendán, and E. Del Pozo, “Pharmacology and therapeutic potential of sigma1 receptor ligands,” Current Neuropharmacology, vol. 6, no. 4, pp. 344–366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. T. Bardo, J. K. Rowlett, and M. J. Harris, “Conditioned place preference using opiate and stimulant drugs: a meta-analysis,” Neuroscience and Biobehavioral Reviews, vol. 19, no. 1, pp. 39–51, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Chaki, A. Nakazato, L. Kennis et al., “Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450,” European Journal of Pharmacology, vol. 485, no. 1–3, pp. 145–158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Sánchez and M. Papp, “The selective σ2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression,” Behavioural Pharmacology, vol. 11, no. 2, pp. 117–124, 2000. View at Google Scholar · View at Scopus
  30. H. Kim, Y. Kwon, D. Roh et al., “Intrathecal treatment with σ1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice,” British Journal of Pharmacology, vol. 148, no. 4, pp. 490–498, 2006. View at Publisher · View at Google Scholar · View at Scopus